Jill A. Howe - Nov 14, 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Chief Financial Officer
Signature
/s/ Grant Harbert, as Attorney-in-Fact
Stock symbol
LCTX
Transactions as of
Nov 14, 2022
Transactions value $
$0
Form type
4
Date filed
11/16/2022, 03:17 PM
Previous filing
Jun 17, 2022
Next filing
Jan 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Employee Stock Option (right to buy) Award $0 +1M $0.00 1M Nov 14, 2022 Common Shares 1M $1.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option will vest as to one quarter of the shares subject to the option on November 14, 2023, and the balance will vest in 36 successive substantially equal installments thereafter, subject to the reporting person's continuous employment.